Testing eRapa medicine for FAP
Part of Cancer, Digestive system, Genetic & congenital clinical trials.
This trial tests a new medicine called eRapa for people with Familial Adenomatous Polyposis (FAP), a condition that causes many polyps in the colon and raises the risk of cancer. The goal is to see if eRapa can help reduce polyps and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with Familial Adenomatous Polyposis (FAP) and have a genetic test confirming it.
- You have a high-risk feature like many polyps in your colon, rectum, or pouch, or an advanced stage of polyps in the small intestine.
- You are willing to use birth control (or not donate sperm/eggs) during and for 12 weeks after treatment.
- You agree to have an endoscopy (a scope test) as part of the study.
- You do not have any cancer or pre-cancer that was not fully removed, active infections, or a weak immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers access to an experimental drug called eRapa (a form of rapamycin) for people with Familial Adenomatous Polyposis (FAP) who have many polyps in the colon or duodenum. The drug may help reduce polyp growth.
This study tests a new drug called ST316 for people with Familial Adenomatous Polyposis (FAP) who have already had their colon removed. It aims to see if the drug can help control polyps in the remaining rectum or pouch.
This trial tests whether taking vitamin B1 can help people with familial adenomatous polyposis (FAP) reduce the number of polyps in their colon or rectum. It is designed for people who still have most of their bowel and have more than 10 polyps.
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
This trial tests the drug rapamycin to see if it can help prevent polyps from growing in children aged 12 to 17 with familial adenomatous polyposis (FAP). The goal is to find out if it can reduce the number or size of polyps, which may lower the risk of needing surgery.
This early-phase trial studies REC-4881 in adults with familial adenomatous polyposis (FAP), a condition that causes many colon/rectum and duodenal polyps. It aims to see whether the treatment can safely help control or shrink polyp growth in people who have had bowel surgery.
Hear when a new Familial Adenomatous Polyposis (FAP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.